Trials / Terminated
TerminatedNCT03379259
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1 (PD-1). BGB-A317 is a humanized, IgG4-variant monoclonal antibody against PD-1. This study tested the safety and anti-tumor effect of BGB-A333 alone and in combination with BGB-A317 in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-A333 | Anti-PD-L1 antibody |
| DRUG | BGB-A317 | Anti-PD-1 antibodies |
Timeline
- Start date
- 2017-11-27
- Primary completion
- 2020-09-08
- Completion
- 2020-09-08
- First posted
- 2017-12-20
- Last updated
- 2024-10-26
- Results posted
- 2021-11-09
Locations
8 sites across 3 countries: Australia, New Zealand, Spain
Source: ClinicalTrials.gov record NCT03379259. Inclusion in this directory is not an endorsement.